Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Towa to Improve Production Efficiencies and Facilities at Yamagata Plant in Response to Rising Generic Demand
September 3, 2015
- AZ, Daiichi Sankyo Team Up for Development, Commercialization of Nasal Flu Vaccine in Japan
September 3, 2015
- GSK Adjusts Shipments of Hepatitis B Treatment Tenozet Due to Disaster-Stricken Plant Following Tianjin Explosion in China
September 2, 2015
- Pfizer Japan Slapped with Biz Improvement Order over ADR Reporting
September 2, 2015
- Sanofi Names Former Keio University Professor Yuji Sato as R&D Head
September 2, 2015
- Eisai to Develop Insomnia Treatment Lemborexant with Purdue Pharma of US
September 2, 2015
- Genzyme Japan Launches Oral Gaucher’s Disease Treatment Cerdelga
September 2, 2015
- Harvoni, Yervoy, Other New Drugs Hit Japan Market
September 1, 2015
- Baxalta Japan Aims for 6-8% Annual Growth by 2020: President Kawamoto
September 1, 2015
- Merck Serono Initiates Voluntary Recall of Ovulation Inducer Serophene Due to Deviation from In-House Specifications
September 1, 2015
- GSK Paid 9.3 Billion Yen to Physicians, Medical Institutions in 2014
August 31, 2015
- Towa Raises Production Target to 14 Billion Tablets: Pres. Yoshida
August 31, 2015
- Hisamitsu Starts PII Study of Analgesic Transdermal Patch for Lower Back Pain in Japan
August 31, 2015
- Seikagaku to Cease Development of Rheumatoid Arthritis Treatment Licensed from Can-Fite
August 31, 2015
- Takeda Inks Deal with Nanotherapeutics to Expand Vaccine Technology Rights
August 28, 2015
- MTPC Chief Hints at No Major Merger, Plans Departure from Go-It-Alone Policy
August 28, 2015
- Jardiance Reduces Cardiovascular Risks: BI, Lilly
August 28, 2015
- Ono Files for Multiple Myeloma Treatment Carfilzomib in Japan
August 27, 2015
- Lixiana Recommended by UK’s NICE as Venous Thromboembolism Treatment Under National Health Service: Daiichi Sankyo
August 27, 2015
- Tresiba Approved for Pediatric Use: Novo Nordisk
August 27, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…